Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amicus Therapeutics (FOLD) Liabilities and Shareholders Equity: 2009-2025

Historic Liabilities and Shareholders Equity for Amicus Therapeutics (FOLD) over the last 16 years, with Sep 2025 value amounting to $868.8 million.

  • Amicus Therapeutics' Liabilities and Shareholders Equity rose 10.46% to $868.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.3 billion, marking a year-over-year increase of 7.35%. This contributed to the annual value of $785.0 million for FY2024, which is 0.92% up from last year.
  • Amicus Therapeutics' Liabilities and Shareholders Equity amounted to $868.8 million in Q3 2025, which was up 6.56% from $815.3 million recorded in Q2 2025.
  • Amicus Therapeutics' 5-year Liabilities and Shareholders Equity high stood at $956.7 million for Q3 2021, and its period low was $700.5 million during Q1 2023.
  • In the last 3 years, Amicus Therapeutics' Liabilities and Shareholders Equity had a median value of $777.9 million in 2023 and averaged $771.8 million.
  • Its Liabilities and Shareholders Equity has fluctuated over the past 5 years, first climbed by 12.18% in 2021, then declined by 20.61% in 2022.
  • Over the past 5 years, Amicus Therapeutics' Liabilities and Shareholders Equity (Quarterly) stood at $905.1 million in 2021, then decreased by 19.99% to $724.2 million in 2022, then rose by 7.42% to $777.9 million in 2023, then grew by 0.92% to $785.0 million in 2024, then climbed by 10.46% to $868.8 million in 2025.
  • Its Liabilities and Shareholders Equity stands at $868.8 million for Q3 2025, versus $815.3 million for Q2 2025 and $789.8 million for Q1 2025.